Cytosorbents Corporation
CTSO
$0.80
$0.056.67%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 9.49M | 9.62M | 8.73M | 6.52M | 8.61M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.49M | 9.62M | 8.73M | 6.52M | 8.61M |
| Cost of Revenue | 2.82M | 2.80M | 2.52M | -247.90K | 3.36M |
| Gross Profit | 6.67M | 6.81M | 6.21M | 6.77M | 5.26M |
| SG&A Expenses | 8.41M | 9.17M | 8.43M | 9.83M | 8.16M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.15M | 13.23M | 12.61M | 10.88M | 13.34M |
| Operating Income | -2.66M | -3.62M | -3.89M | -4.36M | -4.73M |
| Income Before Tax | -3.57M | 1.95M | -1.48M | -9.57M | -2.77M |
| Income Tax Expenses | -401.00K | -- | -- | -1.69M | -- |
| Earnings from Continuing Operations | -3.17M | 1.95M | -1.48M | -7.88M | -2.77M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.17M | 1.95M | -1.48M | -7.88M | -2.77M |
| EBIT | -2.66M | -3.62M | -3.89M | -4.36M | -4.73M |
| EBITDA | -2.30M | -3.21M | -3.52M | -3.97M | -4.35M |
| EPS Basic | -0.05 | 0.03 | -0.02 | -0.14 | -0.05 |
| Normalized Basic EPS | -0.03 | 0.02 | -0.02 | -0.11 | -0.03 |
| EPS Diluted | -0.05 | 0.03 | -0.02 | -0.14 | -0.05 |
| Normalized Diluted EPS | -0.03 | 0.02 | -0.02 | -0.11 | -0.03 |
| Average Basic Shares Outstanding | 62.75M | 62.61M | 60.73M | 54.71M | 54.45M |
| Average Diluted Shares Outstanding | 62.75M | 67.17M | 60.73M | 54.71M | 54.45M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |